Evaluation of population pharmacokinetics and exposure-response relationship with coadministration of amlodipine besylate and olmesartan medoxomil

Journal of Clinical Pharmacology

Volumn 48, Issue 7, 2008, Pages 823-836

  Rohatagi, Shashank ^a   Carrothers, Timothy J ^b   Kshirsagar, Smita ^b   Khariton, Tatiana ^b   Lee, James ^a   Salazar, Daniel ^a,c  

^a DAIICHI SANKYO INC   (United States)

^b PHARSIGHT CORPORATION   (United States)

^c ACCP ^*

Author keywords

Amlodipine; Exposure response; Olmesartan; Population pharmacokinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; AMLODIPINE BESYLATE; AMLODIPINE BESYLATE PLUS OLMESARTAN MEDOXOMIL; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; OLMESARTAN;

AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY WEIGHT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARTMENT MODEL; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG EXPOSURE; HUMAN; HYPERTENSION; INFORMATION PROCESSING; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NEGRO; PHARMACOKINETICS; POPULATION PHARMACOKINETICS; POPULATION RESEARCH; QUANTITATIVE ANALYSIS; RACE DIFFERENCE; SEX DIFFERENCE; STATISTICAL MODEL; VOLUNTEER;

ADULT; AGE FACTORS; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; SEX CHARACTERISTICS; TETRAZOLES;

EID: 45749092989     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270008317847     Document Type: Article

References (22)

1. Norvasc [prescribing information]. New York: Pfizer Labs ; 2005.
2. Benicar [prescribing information]. Parsippany, NJ: Daiichi Sankyo, Inc ; 2006.
3. Salazar D., Lee J., Shenouda M., Rohatagi S. Lack of pharmacokinetic (PK) drug interaction between olmesartan medoxomil (OM) and amlodipine besylate (AM) during coadministration [abstract]. Presented: at American Society of Hypertension (ASH) Annual Meeting ; May 2007 ; Chicago, IL.
4. Haworth S., Heyrman R., Singh Bathala M., et al. The bioavailability (BAV) of a fixed-dose combination of olmesartan medoxomil (OM) and amlodipine besylate (AM) is unaffected by food [abstract]. Presented at: American Society of Hypertension (ASH) Annual Meeting ; May 2007 ; Chicago, IL.
5. Rohatagi S., Haworth S., Heyrman R., et al. Low and high doses of a fixed-dose combination of olmesartan medoxomil (OM) and amlodipine besylate (AM) are bioequivalent (BEQ) to free combination of the agents [abstract]. Presented at: American Society of Hypertension (ASH) Annual Meeting ; May 2007 ; Chicago, IL.
6. Laeis P., Puchler K., Kirch W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens Suppl. 2001 ; 19: S21 - S32.
7. Schwocho LR, Masonson HN Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol. 2001 ; 41: 515-527.
8. von Bergmann K., Laeis P., Puchler K., Sudhop T., Schwocho LR, Gonzalez L. Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. J Hypertens Suppl. 2001 ; 19: S33 - S40.
9. Abernethy DR The pharmacokinetic profile of amlodipine. Am Heart J. 1989 ; 118: 1100-1103.
10. Abernethy DR, Gutkowska J., Lambert MD Amlodipine in elderly hypertensive patients: pharmacokinetics and pharmacodynamics. J Cardiovasc Pharmacol. 1988 ; 12 (suppl 7). S67 - S71.
11. Csajka C., Buclin T., Fattinger K., Brunner HR, Biollaz J. Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers. Clin Pharmacokinet. 2002 ; 41: 137-152.
12. Yoshihara K., Gao Y., Shiga H., Wada DR, Hisaoka M. Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients. Clin Pharmacokinet. 2005 ; 44: 1329-1342.
13. Beal SL, Sheiner LB, eds. NONMEM User's Guides. Hanover, MD: GloboMax, LLC ; 1989-1998.
14. US Department of Health and Human Sciences, Food and Drug Administration. Guidance for Industry Population Pharmacokinetics. Available at: http://www.fda.gov/cder/guidance/1852fnl.pdf. Accessed October 2007.
15. Flynn JT, Nahata MC, Mahan JD Jr, Portman RJ Population pharmacokinetics of amlodipine in hypertensive children and adolescents. J Clin Pharmacol. 2006 ; 46: 905-916.
16. Meredith PA, Elliott HL Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet. 1992 ; 22: 22-31.
17. Kreutz R., Pulcher K. Combination therapy of olmesartan medoxomil with amlodipine or atenolol maintains steady state pharamcokinetics of each drug unchanged. J Hypertens. 2004 ; 22 (suppl 2). S244.
18. Rump LC, Sellin L., Laeis P. Combination of the angiotensin IIreceptor antagonist olmesartan medoxomil with amlodipine: pharmacokinetics, safety and tolerability in healthy male subjects. J Hypertens. 2004 ; 22 (suppl 1). 145S.
19. Gao C., Lertratanakul A. Data on file. Parsippany, NJ: Daiichi Sankyo, Inc; 2002.
20. Gualdiero P., Niebauer J., Addison C., Clark SJ, Coats AJ Clinical features, anthropometric characteristics, and racial influences on the 'white-coat effect' in a single-centre cohort of 1553 consecutive subjects undergoing routine ambulatory blood pressure monitoring. Blood Press Monit. 2000 ; 5: 53-57.
21. Douglas JG, Bakris GL, Epstein M., et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003 ; 163: 525-541.
22. Guyton AC Blood pressure control: special role of the kidneys and body fluids. Science. 1991 ; 252: 1813-1816.